This week I had a chance to interview Dr. Vivian Fonseca on the use of GLP-1 agonists, and he shared his thoughts on why these medications are a logical choice. He also gave us a little information on a study using GLP-1 agonists with insulin, and why he thinks the …

Last month I had a chance to chat with Vivian A. Fonseca, MD, FRCP, Tulane University Medical Center, about the GLP-1 analogs….

For the complete article, Disease Progression in Type 2 Diabetes, and information on other aspects of GLP-1 treatment, please visit Novo Nordisk’s diabetesinamerica at www.novomedlink.com/diabetes/diabetes-in-america.

We are less than two weeks away from the American Diabetes Association’s 71st Scientific Sessions in San Diego, and we are starting to get a glimpse of what is going to be on the agenda. In addition to multiple education sessions and data on the treatment of diabetes there are …

Lately I have been doing a lot of education classes for patients and when it comes to complications of diabetes, patients often want to focus (no pun intended) on vision problems. During my discussions it appears that the fear of losing the ability to drive worries them a lot, and …

Edited by Trisha Dunning AM, RN, MEd, PhD, CDE, FRCNA and Glenn Ward MBBS, BSc, DPhil (Oxon), FRACP, FRCPath Mr. TE was an inpatient and was referred to a diabetes educator. Mr. TE is a 78-year-old man with type 2 diabetes who has a history of cancer and was referred …

Facts of Diabetic Eye Disease: another American becomes legally blind from diabetic retinopathy every 30 minutes. There is no independent tracking of irreparable vision loss from other eye diseases commonly associated with diabetes (retinal vascular occlusion, AION, glaucoma)….

  Germany & France suspend the use of Actos, a TZD diabetes drug, due to worries about a possible link to bladder cancer. Interim results from trials in the U.S. one of which began in 2003 and is slated to last 10 years, have so far not confirmed a clear …

Welcome to our first edition of our new GLP-1 education series. I am sure that every one of you is familiar with the use of GLP-1 agonists in the treatment of diabetes. Ever since Bayliss and Starling discovered secretin in 1902, and speculated that signals arising from the gut after …

For the complete article, The Incretin Effect, and information on other aspects of GLP-1 treatment, please visit Novo Nordisk’s diabetesinamerica at www.novomedlink.com/diabetes/diabetes-in-america.